Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note published on Monday,Benzinga reports. They currently have a $18.00 price target on the stock.

Separately, Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Stock Down 0.1 %

COYA stock opened at $7.24 on Monday. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.69. The firm has a market cap of $120.98 million, a P/E ratio of -11.14 and a beta of 0.46. The company’s 50-day simple moving average is $7.10 and its 200-day simple moving average is $7.02.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, analysts anticipate that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Insider Transactions at Coya Therapeutics

In related news, CEO Arun Swaminathan bought 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares during the period. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics in the 3rd quarter valued at about $169,000. Renaissance Technologies LLC purchased a new stake in Coya Therapeutics during the second quarter worth about $101,000. Finally, Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics during the second quarter worth about $61,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.